Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965135 | 0.82 | CYP19A1 (0.70) | CYP19A1CYP2C19NOTUMCYP2D6 | |
| SCHEMBL9945323 | 0.81 | CYP19A1 (0.68) | CYP19A1CYP2C19NOTUM | |
| SCHEMBL5865736 | 0.80 | CYP19A1 (1.00) | CYP19A1 | |
| SCHEMBL10568092 | 0.79 | CYP19A1 (0.65) | CYP19A1CYP2C19NOTUMADRB2 | |
| SCHEMBL27851957 | 0.78 | CYP19A1 (0.63) | CYP19A1CYP2C19NOTUM | |
| SCHEMBL10362139 | 0.78 | CYP19A1 (0.63) | CYP19A1CYP2C19NOTUM | |
| SCHEMBL9945342 | 0.77 | CYP19A1 (1.00) | CYP19A1CYP2C19 | |
| SCHEMBL10564810 | 0.73 | CYP19A1 (0.57) | CYP19A1CYP2C19NOTUMADRB2 | |
| SCHEMBL406304 | 0.72 | CYP19A1 (0.55) | CYP19A1CYP2C19NOTUMCYP2D6 | |
| SCHEMBL9945331 | 0.72 | CYP19A1 (0.58) | CYP19A1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4845227-A | ANTITUMOR, ENZYME INHIBITORS | ELI LILLY AND COMPANY (US) | 1989-07-04 | — | — | US | claimed |
| EP-0165778-B1 | AROMATASE INHIBITING 1,2,3-TRIAZOL-1-YL, TETRAZOL-1-YL, AND TETRAZOL-2-YL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1989-02-15 | — | — | EP | claimed |
| US-4801594-A | AZOLES, ANTIESTROGEN, ANTICARCINOGENIC | ELI LILLY AND COMPANY (US) | 1989-01-31 | — | — | US | claimed |
| EP-0165778-A1 | Aromatase inhibiting 1,2,3-triazol-1-yl, tetrazol-1-yl, and tetrazol-2-yl compounds | ELI LILLY AND COMPANY (US) | 1985-12-27 | — | — | EP | claimed |
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| WO-2012082746-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-4845227-A | ANTITUMOR, ENZYME INHIBITORS | ELI LILLY AND COMPANY (US) | 1989-07-04 | — | — | US | disclosed |
| EP-0165778-B1 | AROMATASE INHIBITING 1,2,3-TRIAZOL-1-YL, TETRAZOL-1-YL, AND TETRAZOL-2-YL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1989-02-15 | — | — | EP | disclosed |
| US-4801594-A | AZOLES, ANTIESTROGEN, ANTICARCINOGENIC | ELI LILLY AND COMPANY (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0165778-A1 | Aromatase inhibiting 1,2,3-triazol-1-yl, tetrazol-1-yl, and tetrazol-2-yl compounds | ELI LILLY AND COMPANY (US) | 1985-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CYP19A1 898/4885CYP2C19 691/4885NOTUM 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.